Ishibashi Y, Kobayashi H, Ando T, Okajima K, Oki T, Tsuda Y, Shinoda Y, Sawada R, Tanaka S. Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study. World J Orthop 2024; 15(12): 1155-1163 [PMID: 39744733 DOI: 10.5312/wjo.v15.i12.1155]
Corresponding Author of This Article
Hiroshi Kobayashi, PhD, Department of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku 113-8655, Tokyo, Japan. hkobayashi-tky@umin.ac.jp
Research Domain of This Article
Orthopedics
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yuki Ishibashi, Hiroshi Kobayashi, Toshihiko Ando, Kouichi Okajima, Takahiro Oki, Yusuke Tsuda, Sakae Tanaka, Department of Orthopaedic Surgery, The University of Tokyo, Bunkyo-ku 113-8655, Tokyo, Japan
Yusuke Shinoda, Department of Rehabilitation, The Saitama Medical University, Morohongo 350-0495, Saitama, Japan
Ryoko Sawada, Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Hyogo, Japan
Author contributions: Ishibashi Y and Kobayashi H wrote the manuscript and reviewed the relevant literature; Okajima K, Oki T, Tsuda Y, Shinoda Y, Sawada R, and Tanaka S contributed to the conception and design of the study and critically revised the manuscript. All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the University of Tokyo Hospital’s institutional review board (approval number: 11019). All study procedures followed the ethical standards of the 1975 Helsinki Declaration (as revised in 2000) and national law.
Informed consent statement: As we use a blanket consent system, no consent form was provided for this study.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroshi Kobayashi, PhD, Department of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku 113-8655, Tokyo, Japan. hkobayashi-tky@umin.ac.jp
Received: August 21, 2024 Revised: October 14, 2024 Accepted: November 8, 2024 Published online: December 18, 2024 Processing time: 118 Days and 2.2 Hours
Abstract
BACKGROUND
Accurate data on the prognosis of bone metastases are necessary for appropriate treatment. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of gene mutation-negative non-small cell lung cancer (GMN-NSCLC).
AIM
To investigate the prognostic factors in patients with bone metastases from GMN-NSCLC following ICI use.
METHODS
This retrospective cohort study included 45 patients with GMN-NSCLC who were treated for bone metastases from 2017 to 2022 and received chemotherapy after diagnosis. Using Kaplan–Meier curves and Cox proportional hazards models, we evaluated the association between overall survival (OS) and clinical parameters, including serum biochemical concentrations and blood cell count.
RESULTS
Univariate analysis showed that Eastern Cooperative Oncology Group performance status ≤ 1 and the use of ICIs and bone-modifying agents after bone metastasis diagnosis were significantly associated with a favorable OS. Multivariate analysis revealed that ICI use after bone metastasis diagnosis was significantly associated with a favorable OS.
CONCLUSION
ICI use after bone metastasis diagnosis may be a favorable prognostic factor in patients with bone metastases of GMN-NSCLC. Consideration of ICI treatment for bone metastasis and GMN-NSCLC is warranted to establish a more accurate predictive nomogram for patients with bone metastasis.
Core Tip: Use of Immune checkpoint inhibitors after bone metastasis diagnosis may be a favorable prognostic factor in patients with bone metastases from gene mutation-negative non-small cell lung cancer.
